S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
Log in
NASDAQ:CBIO

Catalyst Biosciences Stock Forecast, Price & News

$5.85
-0.10 (-1.68 %)
(As of 11/30/2020 11:07 AM ET)
Add
Compare
Today's Range
$5.83
Now: $5.85
$6.00
50-Day Range
$4.61
MA: $5.57
$6.41
52-Week Range
$3.43
Now: $5.85
$8.94
Volume3,261 shs
Average Volume274,202 shs
Market Capitalization$129.27 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Read More
Catalyst Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-871-0761
Employees34

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Price / Sales12,927.33
Book Value$4.26 per share

Profitability

Net Income$-55,180,000.00

Miscellaneous

Market Cap$129.27 million
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$5.85
-0.10 (-1.68 %)
(As of 11/30/2020 11:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

How has Catalyst Biosciences' stock price been impacted by COVID-19?

Catalyst Biosciences' stock was trading at $4.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CBIO stock has increased by 23.2% and is now trading at $5.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Catalyst Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Catalyst Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Catalyst Biosciences?

Wall Street analysts have given Catalyst Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalyst Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Catalyst Biosciences
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.08.
View Catalyst Biosciences' earnings history
.

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences shares reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CBIO?

4 brokers have issued twelve-month price objectives for Catalyst Biosciences' stock. Their forecasts range from $18.00 to $25.00. On average, they anticipate Catalyst Biosciences' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 252.9% from the stock's current price.
View analysts' price targets for Catalyst Biosciences
.

Are investors shorting Catalyst Biosciences?

Catalyst Biosciences saw a decline in short interest during the month of October. As of October 30th, there was short interest totaling 1,110,000 shares, a decline of 17.8% from the October 15th total of 1,350,000 shares. Based on an average trading volume of 230,400 shares, the days-to-cover ratio is presently 4.8 days.
View Catalyst Biosciences' Short Interest
.

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Celsion (CLSN).

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the following people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 60, Pay $743.5k)
  • Dr. Howard Levy, Chief Medical Officer (Age 66, Pay $533.74k)
  • Mr. Clinton Musil, Chief Financial Officer (Age 38)
  • Ms. Ana Kapor, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Amanda Hill, Sr. Director of HR
  • Mr. Jeffrey Landau, Sr. VP of Bus. Devel.
  • Dr. Grant Blouse, Sr. VP of Translational Research
  • Mr. Charles J. Democko, Sr. VP of Regulatory Affairs (Age 65)
  • Dr. Anju Chatterji Ph.D., Sr. VP of Biologics Devel. & Manufacturing

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (6.39%), BlackRock Inc. (5.79%), State Street Corp (1.06%), Caas Capital Management LP (0.71%), M Holdings Securities Inc. (0.58%) and Arrowstreet Capital Limited Partnership (0.37%). Company insiders that own Catalyst Biosciences stock include Eddie Williams, Howard Levy, John P Richard, Nassim Usman and Veronica Cai.
View institutional ownership trends for Catalyst Biosciences
.

Which major investors are selling Catalyst Biosciences stock?

CBIO stock was sold by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, Amtrust Financial Services Inc., M Holdings Securities Inc., Connor Clark & Lunn Investment Management Ltd., and Squarepoint Ops LLC.
View insider buying and selling activity for Catalyst Biosciences
.

Which major investors are buying Catalyst Biosciences stock?

CBIO stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, BlackRock Inc., State Street Corp, JPMorgan Chase & Co., AQR Capital Management LLC, Wedbush Securities Inc., Trexquant Investment LP, and Jane Street Group LLC. Company insiders that have bought Catalyst Biosciences stock in the last two years include Eddie Williams, Howard Levy, John P Richard, Nassim Usman, and Veronica Cai.
View insider buying and selling activity for Catalyst Biosciences
.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $5.95.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $131.48 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($4.60) on an earnings per share basis. Catalyst Biosciences employs 34 workers across the globe.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is www.catalystbiosciences.com.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.